NIPT in India: How It Works, Cost, Accuracy and Results

• NIPT is a screening test, not a diagnosis. It tells you the chance of a condition, not a yes-or-no answer. A positive result always needs confirmation by CVS or amniocentesis.
• It is highly accurate for Down syndrome (over 99% detection, false-positive rate under 0.1%), and very good for Edwards and Patau syndromes.
• Do the test at or after 10 weeks of pregnancy. Earlier than that, the result is often unreliable or comes back as 'no result'.
• NIPT does NOT detect structural birth defects, most single-gene disorders (like thalassemia), or developmental conditions. You still need the anomaly scan and other antenatal care.
• In India, cost ranges from about Rs 17,000 (basic 3-trisomy panel) to Rs 35,000 (comprehensive panel with microdeletions).
• By law, Indian NIPT reports do not reveal your baby's sex, even though the technology can detect it.

NIPT is built on a remarkable fact: small fragments of your developing baby's DNA circulate in your own bloodstream all through pregnancy. These fragments are called cell-free fetal DNA (cfDNA). They actually come from the placenta, whose cells share the baby's genetic material and are constantly being shed into your circulation, where they mix with your own cell-free DNA.

Small amounts of fetal cfDNA can be picked up from around 7 weeks, but it is only by about 10 weeks that the 'fetal fraction' (the share of cfDNA that is the baby's rather than yours) reliably reaches roughly 4 to 10 per cent, which is enough for an accurate test. This is why 10 weeks is the standard earliest timing.

The test itself is simple for you: one tube of blood from your arm, no fasting, no risk to the pregnancy. In the lab, the cell-free DNA is sequenced and each fragment is mapped to its chromosome and counted. If your baby has a trisomy (an extra copy of a chromosome), there is a slight but measurable excess of fragments from that chromosome in your blood. That tiny excess is what the test detects.

Accuracy is far higher than older screening tests. For Down syndrome (trisomy 21), NIPT correctly identifies more than 99 per cent of affected pregnancies, with a false-positive rate under 0.1 per cent (fewer than 1 in 1,000 unaffected pregnancies get a positive flag). Compare that with the standard dual-marker and NT-scan combined screening, which detects around 85-90 per cent with a 5 per cent false-positive rate. For Edwards syndrome (trisomy 18) accuracy is similar (around 98 per cent), and for Patau syndrome (trisomy 13) it is slightly lower.

One important Indian-law point: the technology can read the baby's sex from the Y chromosome, but the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act, 1994 prohibits prenatal sex determination. So Indian NIPT reports never disclose fetal sex, even though the test could. If you have seen ads for a so-called gender blood test, this is the law you are running into.

Finally, remember the most important limitation up front: NIPT is a screening test. A negative (low-chance) result is very reassuring for the conditions it covers, but it does not rule out every genetic condition or any structural birth defect, and a positive result still has to be confirmed before any decision is made.

What NIPT screens for depends on the panel you choose. The conditions break down roughly like this:

The three main trisomies (all panels). Trisomy 21 (Down syndrome) is the most common and is compatible with a meaningful life with support. Trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) are usually severe, with most pregnancies ending in miscarriage, stillbirth, or death in the first year. Detection is highest for Down syndrome.

Sex chromosome conditions (extended panels). These include Turner syndrome (a single X), Klinefelter syndrome (XXY), Triple X (XXX) and XYY. Their impact ranges widely, from significant (Turner syndrome) to often mild or symptom-free (XXX, XYY). Accuracy here is slightly lower and false positives slightly higher than for the main trisomies, because of placental and maternal mosaicism affecting these chromosomes.

Microdeletions (comprehensive panels). These are tiny missing pieces of a chromosome, such as DiGeorge syndrome (22q11.2 deletion), Cri-du-chat, Prader-Willi and Angelman syndromes. Each is individually rare. Detection rates are lower than for trisomies and false-positive rates are higher, so a positive microdeletion result especially needs careful counselling and confirmation.

What NIPT does NOT detect is just as important to understand:

Choosing a panel is one of the more confusing parts of NIPT, because providers offer different bundles at different prices. Here is a practical way to think about it, with India costs as a guide.

Basic three-trisomy panel (around Rs 17,000-22,000). Covers trisomy 21, 18 and 13. This is the minimum panel and covers the highest-impact, most common conditions at the lowest cost. Reasonable for most couples with no specific risk factors.

Extended panel with sex chromosome conditions (around Rs 20,000-28,000). Adds Turner, Klinefelter, Triple X and XYY. Worth considering if you want early diagnosis and planning information, accepting that some of these conditions are mild while Turner syndrome is more significant.

Comprehensive panel with microdeletions (around Rs 25,000-35,000). Adds specific microdeletion syndromes. Because these are individually rare and the test is less accurate for them, you get more false positives needing follow-up. Discuss with a genetic counsellor whether the extra detection is worth the extra complexity. India-context detail on what microdeletions and 'soft markers' actually mean is covered in our guide to birth-defects screening and soft markers.

Advanced panels (around Rs 30,000-50,000). Add rare aneuploidies and a few paternal-age-related single-gene conditions. The extra yield over the comprehensive panel is modest for most couples.

Our companion piece on NIPT cost and accuracy in India goes deeper into platform-by-platform performance if you want to compare numbers before booking.

There is no single right answer. The best pathway depends on your budget, how much certainty you want, and what you would do with the results. Three common routes:

NIPT as first-line screening. Increasingly common in urban Indian private practice when cost allows. Its much higher accuracy means far fewer false alarms, less anxiety, and fewer invasive diagnostic procedures. It can also be done a little earlier than combined screening. The trade-off is cost and the fact that NIPT alone does not give the structural information an NT scan provides. Many fetal medicine units therefore offer NIPT plus an NT scan for the most complete first-trimester picture.

Combined screening first, NIPT as backup. The cost-saving route. You do the cheaper dual-marker and NT combined screening first (around Rs 4,000-8,000). Most results are low risk and need nothing more. If the result is high risk, NIPT is then used to clarify, and most high-risk combined-screening results turn out to be false alarms that NIPT reassures. The final accuracy is the same as NIPT first-line, at lower average cost, but with more anxiety for the few who get a high-risk first result.

Skip chromosomal screening. A completely legitimate choice for couples who would continue the pregnancy whatever the result. The standard antenatal care, including the 18-22 week TIFFA anomaly scan, still applies. Screening is offered as the standard of care, but you are never obliged to accept it.

NIPT is especially worth considering if you are 35 or older, have had a previous pregnancy with a chromosomal condition, or simply want maximum reassurance with the fewest invasive procedures. Your weight matters too: a higher BMI lowers the fetal fraction and raises the chance of a 'no result'.

A positive NIPT result is frightening, so the single most important thing to know is this: a positive result is not a diagnosis. It means the chance of the condition is increased, and it must be confirmed before any decision is made. The reason is something called positive predictive value (PPV).

PPV is the chance that a positive result is actually true, and it depends not just on the test but on your own baseline risk. An example makes this clear. For Down syndrome in a 25-year-old with no risk factors, the baseline chance is low, so even with NIPT's excellent accuracy only about 45 per cent of positive results are true positives (and 55 per cent are false alarms). For a 40-year-old, whose baseline chance is much higher, the PPV rises above 90 per cent. The exact same test gives a very different meaning depending on your age. PPV for Edwards and Patau syndromes, and for microdeletions, is generally lower still because those conditions are rarer.

So a positive result calls for confirmation, not panic. The next step is diagnostic testing:

India's NIPT market has matured, with several home-grown and international options. The platform matters less than picking a provider who offers genuine genetic counselling alongside the test, because a result is only as useful as the explanation that comes with it.

Indian providers. Strand Life Sciences, MedGenome and MapMyGenome run validated platforms with national sample collection, counsellor support and relatively fast turnaround (often 5-10 days).

International platforms via Indian labs. The Harmony test (Roche) is offered through Dr Lal PathLabs and other chains; Panorama (Natera) is available through some labs and is particularly strong for sex chromosome conditions and microdeletions. Turnaround is typically 7-14 days as samples go to a central lab.

Lab chains and hospitals. Dr Lal PathLabs, Metropolis, Thyrocare, SRL and Apollo Diagnostics offer NIPT through partnerships, and most large maternity hospitals (Cloudnine, Apollo, Fortis, Manipal, Fernandez and others) bundle it with genetic counselling and OB review.

Before you book, it is worth asking a few specific questions:

Cost is the main practical barrier. NIPT runs from about Rs 17,000 (basic 3-trisomy) to Rs 35,000 (comprehensive with microdeletions), with advanced panels reaching Rs 50,000. That is several times the price of combined first-trimester screening, so it is reasonable to weigh it carefully.

Insurance. Most standard health policies in India do not cover NIPT, though some premium plans and corporate group policies with maternity benefits now include genetic screening up to a limit. Always check your specific policy wording before assuming coverage, and note that maternity benefits usually have a waiting period. Government schemes such as Ayushman Bharat generally do not currently cover NIPT.

EMI and packages. Several hospital chains and labs offer EMI financing or antenatal packages that fold in NIPT, and some labs run promotional pricing. If cost is a barrier, ask, because options are often not advertised.

Government provision. Some government tertiary hospitals (such as AIIMS, PGIMER and JIPMER) and certain state programmes offer NIPT at subsidised rates for specific indications like advanced maternal age, an abnormal first-trimester screen, or a family history of a chromosomal condition. Entitlements vary by state.

If you are budgeting for the whole pregnancy, it helps to see where NIPT sits alongside other costs such as scans, blood tests and supplements. For population-level cost-effectiveness, combined screening first with NIPT as a backup is generally cheaper; for an individual couple who can afford it and want the least anxiety, NIPT first-line is often the better experience.

NIPT behaves a little differently outside a standard single pregnancy. A genetic counsellor should walk you through your specific situation before booking.

Twins. NIPT can be done in twin pregnancies, but accuracy is slightly lower and panel options are more limited, especially for sex chromosome conditions and microdeletions, because the test cannot easily separate the two babies. Our guide to twin and multiple pregnancy covers the wider monitoring picture, including chorionicity and surveillance.

Triplets or more. NIPT is generally not recommended, because the contribution of each baby to the cfDNA pool cannot be reliably told apart.

Donor egg, donor embryo or surrogacy. Because the cfDNA comes from the placenta, the result reflects the embryo's genetics, not the carrier's. NIPT is valid in these pregnancies, and the carrier's age does not affect accuracy, since it is the baby's genetics that matter. The same biology is why prenatal paternity testing exists in principle, though it is uncommon in India.

Vanishing twin. If one twin stopped developing early, its cfDNA can linger for weeks and skew the result, often as a false positive. Tell your provider, and a delay before testing may be advised.

No-call results. About 1-5 per cent of samples give no clear result, usually from a low fetal fraction (testing too early, or higher BMI). Options are a repeat test after 1-2 weeks, switching to combined screening, or diagnostic testing if risk is high. Many labs repeat a no-call test free, so confirm the policy when you book.

Good counselling is what turns a complex test into a useful one. It should happen both before you decide and after you get the result.

Before the test, you should clearly understand: what your chosen panel detects and what it does not; that NIPT is screening, not diagnosis; the idea of positive predictive value (a positive result is not a definite diagnosis); the no-call rate; and, crucially, what you would do with the results. That last question, more than any other, decides whether the test is right for you. Sources of counselling in India include hospital fetal-medicine units and the genetic counsellors attached to the major NIPT providers. A broader picture of how this fits together is in our guide to prenatal genetic counselling in India.

After a low-risk result, counselling is mainly reassurance: the chance of the screened conditions is very low, standard care continues including the anomaly scan, and any relevant carrier screening can be arranged separately. It should still be said clearly that low-risk for these conditions does not mean no risk for everything.

After a high-risk result, this is the moment that matters most. You should hear the actual PPV for your situation, the next steps for confirmation, the realistic outlook if confirmed, and the support and choices available, with time to talk it through and mental-health support offered.

Counselling is also where carrier screening for conditions NIPT cannot see, such as thalassemia carrier screening for couples and broader genetic carrier screening, gets discussed, helping couples make sense of their own inherited risk.

NIPT is a planned, elective test rather than something you do for symptoms, but there are clear moments to speak to your obstetrician or a fetal medicine specialist:

• American College of Obstetricians and Gynecologists (ACOG) — Prenatal Genetic Screening Tests (FAQ)
• NHS — Screening tests in pregnancy (NIPT and combined screening)
• PCPNDT Act, 1994 — Ministry of Health and Family Welfare, Government of India
• Medical Termination of Pregnancy (Amendment) Act, 2021 — Government of India
• WHO — Congenital disorders (fact sheet)